drug

ARV-806

1 story · latest Aug 4, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Arvinas Inc.

Timeline

Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drug

Aug 4Quarterly updateArvinas Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.